ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
59,495.91
0.63%
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs Yen
153.01
-0.03%
Brent Oil
83.54
-0.11%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Tarsus Pharmaceuticals Inc (TARS)

  7. Tarsus Pharmaceuticals Inc (TARS) ニュース

TARS

Tarsus Pharmaceuticals (TARS)

Tarsus Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:TARS
日付受信時刻ニュースソース見出しコード企業名
2024/05/0206 : 00GlobeNewswire Inc.Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
2024/04/2321 : 30GlobeNewswire Inc.Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/1206 : 57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/1206 : 45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/1206 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/1206 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/0606 : 30GlobeNewswire Inc.Tarsus to Participate at Upcoming Investor ConferencesNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/0606 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/0522 : 30GlobeNewswire Inc.Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex BlepharitisNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/0207 : 26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/0207 : 17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/0114 : 07GlobeNewswire Inc.Tarsus Announces Pricing of $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/0107 : 08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/0106 : 37GlobeNewswire Inc.Tarsus Announces Proposed $100.0 Million Public OfferingNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/03/0106 : 32Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/02/2806 : 22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/02/2806 : 02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TARSTarsus Pharmaceuticals Inc
2024/02/2720 : 00GlobeNewswire Inc.Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business AchievementsNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/02/2222 : 00GlobeNewswire Inc.Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme DiseaseNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/02/2107 : 00GlobeNewswire Inc.Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024NASDAQ:TARSTarsus Pharmaceuticals Inc
2024/02/0107 : 00GlobeNewswire Inc.Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks ConferenceNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/01/3106 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/01/2307 : 05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/01/1906 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
2024/01/0823 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARSTarsus Pharmaceuticals Inc
2023/12/3007 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
2023/12/2806 : 23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
2023/12/2307 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
2023/12/2106 : 49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
2023/12/2008 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARSTarsus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:TARS

最近閲覧した銘柄

COIN
SOLUSD
Solana
USOTC
BNPQY
BNP Paribas (QX)
NYSE
DIS
Walt Disney
NASDAQ
AAPL
Apple
NYSE
CVX
Chevron
COIN
BTCUSD
Bitcoin
USOTC
RHHBY
Roche (QX)
NYSE
BAC
Bank of America
NYSE
VZ
Verizon Communications
AMEX
XLE
Energy Select Sector SPDR
USOTC
DTEGY
Deutsche Telekom (QX)
SPI
SP500
S&P 500
NASDAQ
MSFT
Microsoft
NYSE
MRK
Merck
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有